Peihong Wu

机构：Hebei Medical University, Guangxi University, Sun Yat-sen University, Hangzhou Normal University, Sichuan University, West China Hospital of Sichuan University, Sun Yat-sen University Cancer Center, First Affiliated Hospital of Hebei Medical University, State Key Laboratory of Oncology in South China · ORCID：0000-0001-8008-1872

发表论文 170 篇 · 总被引 3906 次 · h-index 37

代表论文

• Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study (2023 · Signal Transduction and Targeted Therapy · 被引 128)
• Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy (2023 · Cancer · 被引 19)
• Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study (2024 · International Journal of Surgery · 被引 15)
• Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study (2024 · Cancer Medicine · 被引 11)
• Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC (2023 · Therapeutic Advances in Medical Oncology · 被引 11)
• Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based study (2024 · British Journal of Cancer · 被引 7)